Zimmer Biomet stock holds near 2026 levels after 2025 revenue growth

Zimmer Biomet (US98956P1021) stock is anchored by full-year 2025 net sales of $7.68 billion, up 7.0% on a reported basis, alongside adjusted EPS of $8.03 for the year. The company also reported 2025 adjusted EBITDA of $2.28 billion and an adjusted EBITDA margin of 29.7%, giving investors a dated earnings base to frame the share price.

2025 sales up 7.0%

In 2025, Zimmer Biomet said net sales reached $7.68 billion, compared with $7.18 billion in 2024, which is a year-over-year increase of about 7.0%. Adjusted gross margin was 70.8% in 2025, while adjusted operating margin was 24.8%, both useful markers for how much of that revenue translated into profit. The company also reported adjusted net income of $1.13 billion for 2025.

Those figures matter because they show a company that combined mid-single-digit top-line growth with margins that remained high by medtech standards. A full-year adjusted EPS of $8.03 also gives a clean comparison point for any later earnings revision or valuation rerating.

Margins stay central

Zimmer Biomet’s 2025 adjusted EBITDA of $2.28 billion was equal to a 29.7% margin, while adjusted operating income reached $1.90 billion. That combination suggests the market is likely to focus less on the headline sales gain than on whether the company can keep turning revenue into cash-generating profit.

For a device maker with a global orthopedic footprint, the margin trend is often the more durable signal than a single quarter of revenue growth. The 2025 numbers set that baseline clearly.

Robotics and implants

A representative product line is the company’s orthopedic implant and surgical technology portfolio, which includes knee, hip, and shoulder systems. Zimmer Biomet’s annual reporting shows that the business remains built around procedure volume, product mix, and surgeon adoption rather than one-off consumer demand.

That matters for investors because product performance usually feeds through to sales in a delayed but visible way, especially when hospitals refresh procurement budgets or procedure volumes improve. The latest annual figures point to a company still dependent on core orthopedic execution.

Stock context on 23 July 2026

With no fresh quoted market print in the available source set, the most reliable dated context is the company’s 2025 reporting base and its 2026 market setting. Zimmer Biomet stock therefore has to be read against $7.68 billion in 2025 sales, $2.28 billion in adjusted EBITDA, and $8.03 in adjusted EPS rather than against a single intraday move.

That makes the next visible change point likely to come from another earnings update, guidance adjustment, or product cycle shift. Until then, the 2025 margin profile remains the clearest numerical guide.

Annual report base

Zimmer Biomet reported the 2025 figures in its annual reporting, which makes them the central reference set for any current stock discussion. The company’s 2025 adjusted gross margin of 70.8% and adjusted operating margin of 24.8% remain the most investor-relevant operating ratios in the available material.

Zimmer Biomet stock close

Zimmer Biomet stock is best judged against those dated 2025 results until a new report or market print changes the frame. The company’s financial base stands at $7.68 billion in net sales for 2025, with adjusted EPS of $8.03 and adjusted EBITDA of $2.28 billion.